| CAN296 | CBD-rich cannabis extract (Type III strain) |
| CB2 | Cannabinoid receptor type 2 |
| CBC | Cannabichromene |
| CBD | Cannabidiol |
| CD4+ | Cluster of Differentiation 4 helper T cells |
| CD8+ | Cluster of Differentiation 8 cytotoxic T cells |
| DEX | Dexamethasone |
| DMSO | Dimethyl sulfoxide |
| ECS | Endocannabinoid system |
| ELISA | Enzyme-linked immunosorbent assay |
| FBS | Fetal bovine serum |
| FMO | Fluorescence-minus-one |
| GVHD | Graft-versus-host disease |
| HNSCC | Head and neck squamous cell carcinoma |
| HSCT | Hematopoietic stem cell transplantation |
| IFN-γ | Interferon gamma |
| LLLT | Low-level laser therapy |
| MFI | Median fluorescence intensity |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| OLP | Oral lichen planus |
| OPMD | Oral potentially malignant disorder |
| oGVHD | Oral graft-versus-host disease |
| PBMC | Peripheral blood mononuclear cells |
| PBS | Phosphate-buffered saline |
| PDT | Photodynamic therapy |
| PFA | Paraformaldehyde |
| PPAR | Peroxisome proliferator-activated receptor |
| TAC | Tacrolimus |
| T-cell | T lymphocyte |
| TNF-α | Tumor necrosis factor alpha |
| TRP | Transient receptor potential |